Medline Inc. (MDLN) stock analysis
Close on Nov 11, 2026Market cap $55.43BP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak2 of 30 checks passed
Medline passes 2 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 0/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
Guidance raised
Medline raised its full year 2026 Organic Sales outlook on Aug 5, 2026.
Short-term assets cover short-term debts
Current assets are 4.04 times current liabilities.
What to watch
Margin of safety under 20%
The price is 76.0% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $42.16 is above our fair value estimate of $23.96.
Return on capital under 10%
Return on invested capital was 6.6%, below the 10% that usually covers the cost of capital.
High debt
Debt is 107% of shareholders' equity, above the 40% we consider low.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B above the industry
Medline's price-to-book of 4.70 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.22.
Trading above fair value
The share price of $42.16 is above our fair value estimate of $23.96.
Margin of safety under 20%
The price is 76.0% above fair value, so there is no margin of safety.
Growth1/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Guidance raised
Medline raised its full year 2026 Organic Sales outlook on Aug 5, 2026.
Gross margin trend
This company does not report gross profit.
Past performance0/6
Return on equity
Needs positive equity and five years of results.
Return on capital under 10%
Return on invested capital was 6.6%, below the 10% that usually covers the cost of capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health1/6
High debt
Debt is 107% of shareholders' equity, above the 40% we consider low.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals 18.9% of total debt; we look for at least 20%.
Interest not well covered
Operating income covers interest expense 2.5 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 4.04 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.80; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Medline has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$23.96
The share price is 76% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| EV/EBITDA | 16.7× | – | 16.7× | $28.29 | 58% |
| P/B | 3.2× | – | 3.2× | $28.86 | 17% |
| Earnings power | 9.9% cost of equity | – | – | $10.58 | 25% |
| Fair value | $23.96 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $351.64M
- Value traded per 1% price move
- $164.46M
Downside
Medium risk
- Typical loss in a bad month
- 22.2%
- Volatility (annualized)
- 48%
- Sharpe ratio, 1 year
- -0.03
- Beta to the S&P 500 (5Y)
- –
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
Operating margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.5% | – | – | – | |
| Gross profit | +7.8% | – | – | – | |
| Operating income | +3.1% | – | – | – | |
| Free cash flow | -8.3% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 4.29 | |
| Net debt to EBITDA | – | – | 3.30× | |
| Interest coverage | – | – | 2.3× | |
| Capex to revenue | – | – | 1.6% |
Cash use needs five years of cash flow figures
Medline does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$1.16B
- Cash generatingOperating cash flow above zero$1.74B
- Return on assets improvedROA up on the prior year– → 3.2%
- Earnings backed by cashOperating cash flow above net income$1.74B vs $1.16B
- Less leverageLong-term debt to assets fell45.6% → 32.4%
- Better liquidityCurrent ratio rose3.39 → 4.29
- No dilutionShare count did not rise– → 810M
- Gross margin improvedGross margin up on the prior year27.35% → 26.44%
- More efficientAsset turnover rose– → 0.79
See a number that looks wrong?